These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 8672620

  • 1. [Comparative study of the cost-/effectiveness relationship of initial therapy with imipenem/cilastatin in nosocomial pneumonia. Group study].
    Rodloff AC, Laubenthal HJ, Bastian A, Bestehorn K, Büchele G, Gaus W.
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 Apr; 31(3):172-80. PubMed ID: 8672620
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection.
    Dietrich ES, Schubert B, Ebner W, Daschner F.
    Pharmacoeconomics; 2001 Jan; 19(1):79-94. PubMed ID: 11252548
    [Abstract] [Full Text] [Related]

  • 4. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
    Bartoloni A, Strohmeyer M, Corti G, Buonomini MI, Franchino L, Romanelli G, Moretti AM, De Vizzi GB, Petraglia A, Mancini P, Atzeni R, Fogliani V, Giura R, Paradisi F.
    Drugs Exp Clin Res; 1999 Jan; 25(6):243-52. PubMed ID: 10713862
    [Abstract] [Full Text] [Related]

  • 5. Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial.
    Shorr AF, Zadeikis N, Jackson WL, Ramage AS, Wu SC, Tennenberg AM, Kollef MH.
    Clin Infect Dis; 2005 Feb 15; 40 Suppl 2():S123-9. PubMed ID: 15712100
    [Abstract] [Full Text] [Related]

  • 6. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
    Sanz MA, Bermúdez A, Rovira M, Besalduch J, Pascual MJ, Nocea G, Sanz-Rodríguez C, COSTINE Study Group.
    Curr Med Res Opin; 2005 May 15; 21(5):645-55. PubMed ID: 15969864
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy.
    Romanelli G, Cravarezza P, Pozzi A, Franchino L, Ravizzola G, Zulli R, Donati P, Prometti P, Grassi V.
    J Chemother; 2002 Dec 15; 14(6):609-17. PubMed ID: 12583553
    [Abstract] [Full Text] [Related]

  • 9. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections.
    Walters DJ, Solomkin JS, Paladino JA.
    Pharmacoeconomics; 1999 Nov 15; 16(5 Pt 2):551-61. PubMed ID: 10662480
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cost-analysis of imipenem-cilastatin monotherapy compared with clindamycin+aminoglycoside combination therapy for treatment of serious lower respiratory, intra-abdominal, gynecologic, and urinary tract infections.
    Kreter B.
    Clin Ther; 1992 Nov 15; 14(1):110-21. PubMed ID: 1576620
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
    Kuo BI, Fung CP, Liu CY.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May 15; 63(5):361-7. PubMed ID: 10862445
    [Abstract] [Full Text] [Related]

  • 14. [Contribution of imipenem/cilastatin in the treatment of peritonitis: a comparative economic analysis in the case of France].
    Levy E, Levy P.
    J Chir (Paris); 1993 Apr 15; 130(4):200-9. PubMed ID: 8345014
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.
    McKinnon PS, Paladino JA, Grayson ML, Gibbons GW, Karchmer AW.
    Clin Infect Dis; 1997 Jan 15; 24(1):57-63. PubMed ID: 8994756
    [Abstract] [Full Text] [Related]

  • 16. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
    Cherif H, Björkholm M, Engervall P, Johansson P, Ljungman P, Hast R, Kalin M.
    Scand J Infect Dis; 2004 Jan 15; 36(8):593-600. PubMed ID: 15370671
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia.
    McKindley DS, Boucher BA, Hess MM, Croce MA, Fabian TC.
    Pharmacotherapy; 1996 Jan 15; 16(5):924-31. PubMed ID: 8888088
    [Abstract] [Full Text] [Related]

  • 18. Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study.
    Schmitt DV, Leitner E, Welte T, Lode H.
    Infection; 2006 Jun 15; 34(3):127-34. PubMed ID: 16804655
    [Abstract] [Full Text] [Related]

  • 19. [Evidence-based medicine, health costs and treatment of intra-abdominal infection].
    Badía X, Brosa M, Tellado JM.
    Enferm Infecc Microbiol Clin; 1999 Jun 15; 17 Suppl 2():86-94. PubMed ID: 10605193
    [Abstract] [Full Text] [Related]

  • 20. Cost-minimization analysis of piperacillin/tazobactam versus imipenem/cilastatin for the treatment of serious infections: a Canadian hospital perspective.
    Marra FO, Frighetto LO, Marra CA, Sleigh KM, Stiver HG, Bryce EA, Reynolds RP, Jewesson PJ.
    Ann Pharmacother; 1999 Feb 15; 33(2):156-62. PubMed ID: 10084409
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.